Chiesi Farmaceutici S.p.a.

This study tested whether an asthma medication using a new, more environmentally friendly propellant (HFA-152a) is as safe as the same medication using the current standard propellant (HFA-134a). Over 800 adults with moderate to severe asthma participated in this 12-week trial. T…

This study tested if a new combination inhaler (CHF 1535) works better than a standard steroid inhaler (CHF 718) for adults with moderate-to-severe asthma. Over 1,300 participants used one of the two inhalers for 12 weeks. Researchers measured lung function, asthma symptoms, and …

This large, completed study compared a new triple-combination inhaler to a standard dual-combination inhaler for people with chronic obstructive pulmonary disease (COPD). Over 3,400 participants used their assigned inhaler for 52 weeks. The main goal was to see if the triple inha…

This study tested if a new combination inhaler (CHF 1535) was better than a standard steroid inhaler at improving lung function in adults whose asthma was not well-controlled on their current medication. Over 500 participants used one of the two inhalers for 12 weeks while resear…

This study looked at how well a three-in-one inhaler works for people with COPD in their everyday lives. It followed 362 adults in China for 12 weeks to see if the inhaler improved their breathing symptoms and lung function. The goal was to gather real-world evidence on controlli…

This study aimed to understand how a potential new asthma drug is processed by the body. Researchers compared the drug levels in the blood of 25 teenagers and 25 adults with stable asthma after they inhaled a single dose. The main goal was to see if the drug behaves similarly in …

This early-stage study aimed to understand how a drug called cyclosporine, often used after organ transplants, might affect the body's processing of an experimental medication for COPD (CHF6001). Thirty healthy volunteers took the COPD drug alone and then again after taking cyclo…

This study monitored 1005 heart attack patients who received artery-opening procedures to understand the safety of switching from an intravenous blood thinner (cangrelor) to oral blood thinners (clopidogrel, prasugrel, or ticagrelor). Researchers tracked patients for 30 days afte…

This early-stage study tested the safety and how the body processes an inhaled drug called CHF10073, which is being developed for pulmonary fibrosis (lung scarring). It involved 155 healthy volunteers to check for side effects and measure drug levels in the blood and lungs. The m…